OSOlga Vadimovna Stukalova

Olga Vadimovna Stukalova

*This is an algorithmically generated author record based on publicly available information.

Olga Vadimovna Stukalova has a total of 323 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of fractional flow reserve and instantaneous wave-free ratio dynamics in patients with st-segment elevation myocardial infarction and its dependence on the presence of microvascular obstruction in the infarct zone

    by Kh. U. Ibragimova, T. S. Sukhinina, G. K. Arutyunyan, O. V. Stukalova, M. A. Terenicheva, O. A. Saigina, E. V. Merkulov, Х. У. Ибрагимова, Т. С. Сухинина, Г. К. Арутюнян, et al.

    Objective. To analyze the dynamics of coronary physiology indices — fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) — in the infarct-related artery (IRA) and non-infarct-related artery (non-IRA) during the first 24 hours of ST-segment elevation myocardial infarction (STEMI) and in the early postinfarction period, and to assess their dependence on the presence of microvascular obstruction (MVO) in the infarct zone as determined by contrast-enhanced cardiac magnetic resonance imaging (MRI). Materials and methods. FFR and iFR were measured in the IRA and non-IRA after primary percutaneous coronary intervention (pPCI) on the IRA in patients with STEMI and at least one 50–85% stenosis in a non-IRA. Papaverine was used to induce hyperemia for FFR assessment. Cardiac MRI was performed on days 3–5 to evaluate the presence and extent of MVO in the infarct zone. Repeated coronary angiography with FFR and iFR measurement was performed at 30–45 days; based on the results, non-IRA stenting was performed when FFR ≤ 0.80 and/or iFR ≤ 0.89. To achieve the study objective, the dynamics of coronary physiology indices in the IRA and non-IRA were assessed in the overall cohort and in subgroups with and without MVO on MRI. Statistical analysis included the Wilcoxon signed-rank test, the Mann–Whitney U test, and Spearman's correlation. Results. Thirty-two patients were enrolled. MVO was detected in 13 patients (40.6%). No statistically significant changes in FFR or iFR between the index procedure and repeated assessment were found in either the IRA or the non-IRA (p=0.856 and 0.597 for FFR, p=0.092 and 0.511 for iFR, in the IRA and non-IRA, respectively). The presence of MVO with an extent of 2.47% [0.66%; 5.06%] was not associated with significant differences in FFR or iFR dynamics (p=0.488 (FFR), p=0.089 (iFR) in the IRA; p=0.460 (FFR) and 0.144 (iFR) in the non-IRA). MVO extent of 2.47% [0.66%; 5.06%] did not correlate with changes in FFR or iFR in either the IRA or the non-IRA (the most pronounced trend was observed for ΔiFR in the IRA: ρ=−0.529, p=0.063). Categorical classification stability was 92.0% for FFR and 86.0% for iFR. Conclusion. In hemodynamically stable patients with STEMI and intermediate nonIRA stenoses, FFR and iFR values in both the non-IRA and the IRA after pPCI remain stable during the first 24 hours of MI and in the early postinfarction period. Coronary physiology indices (FFR, iFR) can be used for decision-making regarding non-IRA PCI during the index procedure. In patients with STEMI with a median ejection fraction of 52.5% [49.75%; 58.25%] and MVO extent of 2.47% [0.66%; 5.06%], the presence of MVO did not distort the reproducibility of FFR and iFR measurements in the non-IRA and IRA after pPCI.

  • Open Access

    Clinical Applications of Cardiac Magnetic Resonance Imaging in Cardiology. Consensus Statement of the Eurasian Association of Cardiologists (EAC) (2026)

    by O. V. Stukalova, S. A. Aleksandrova, T. B. Dautov, E. I. Zyablova, L. B. Musayeva, E. S. Pershina, S. D. Rud, M. B. Sukhova, V. A. Fokin, S. K. Ternovoy, et al.

    This consensus document summarizes the current role of cardiovascular magnetic resonance (CMR) in contemporary cardiology practice. It integrates the latest evidence, international guideline recommendations, and practical experience regarding the use of CMR in the diagnosis and management of the most common cardiovascular diseases. Particular attention is given to the appropriate clinical indications for CMR, standardized imaging protocols, interpretation of imaging findings, and their impact on clinical decision-making and patient outcomes. The document reviews the application of CMR in ischemic heart disease, cardiomyopathies, myocarditis, inflammatory heart diseases, cardiac tumors, cardio-oncology, and congenital heart disease. Modern techniques for myocardial tissue characterization, including late gadolinium enhancement and parametric mapping, are discussed as essential tools for the non-invasive assessment of myocardial fibrosis, inflammation, infiltration, and viability. Special emphasis is placed on the practical use of CMR in complex clinical scenarios where imaging findings directly influence diagnosis, risk stratification, and therapeutic strategy. This consensus is primarily intended for practicing cardiologists but will also be of value to radiologists, cardiac surgeons, cardiovascular imaging specialists, and other healthcare professionals involved in the care of patients with cardiovascular disease. The authors hope that this document will promote the appropriate and wider implementation of CMR in routine clinical practice, ultimately improving diagnostic accuracy, patient management, and clinical outcomes.

  • Open Access

    Patient profile and clinical features of postinfarction ventricular septal rupture. Seven-year experience at a single center in Russia

    by E. A. Avetisyan, D. V. Pevzner, I. A. Merkulova, A. K. Alieva, L. O. Dulaev, I. T. Zyuryaev, A. D. Levshukov, E. V. Merkulov, A. G. Osiev, A. S. Tereshchenko, et al.

    Aim . To study the clinical and demographic data of a non-selective population of patients with post-infarction ventricular septal rupture (VSR) at a single center in Russia. Material and methods . This single-center, retrospective, observational cohort study included all patients with post-infarction VSR admitted to the Chazov National Medical Research Center of Cardiology in Moscow between 2019 and 2025. Demographics, comorbidities, clinical course, echocardiographic data, frequency and timing of open surgical repair and percutaneous closure, mechanical circulatory support, and patient routing were assessed using descriptive statistics. A search for independent factors influencing the choice of primary intervention was conducted using multiple logistic regression. Results . A total of 94 patients with post-infarction VSR were included in the study between 2019 and 2025. The mean age was 68,5±12 years (women, 56,4%). The most common medical history included hypertension (82/94, 87,2%), diabetes (35/94, 37,2%) and obesity (27/94, 28,7%). An attempt of coronary reperfusion was made in 69,2% of patients (65/94), while only in 28,7% (27/94) it was timely and successful. Cardiogenic shock (CS) occurred in 66% (62/94) of cases, most often stages D 24/62 (38,7%) and E 20/62 (32,3%). Mechanical circulatory support was used in 53,2% of cases. Any curative treatment was performed in 87,2% of cases. Independent predictors of percutaneous closure were pre-intervention CS (8,31 [2,77-24,93], pConclusion . Patients with post-infarction VSR have significant comorbidity. Timely successful coronary reperfusion was achieved in less than a third of patients. A high incidence of end-stage CS is noted, which, along with age over 65,5 years, is an independent predictor of performing percutaneous closure.

  • Open Access

    MRI of the heart for the assessment of structural and functional changes in the myocardium in patients with chronic heart failure.

    by O. Ouelhazi, O. V. Stukalova, S. K. Ternovoy, У. Уельхази

    Chronic heart failure (CHF) is a severe clinical syndrome, which can develop in patients with various heart diseases. Tactics of management of patients with CHF depends on cause of development of this syndrome, therefore exact diagnosis is especially important. Echocardiography (EchoCG) is the main method in algorithm of examination with any cardiological examination, but neither EchoCG, nor other traditional cardiological methods of examination in all clinical situations can reveal cause of development of CHF, therefore search for new diagnostic strategies is important. Objective of the work : to show possibilities of magnetic resonance tomography of heart in examination of patients with chronic heart failure on example of own clinical observations. Materials and methods . Analyzed heart studies performed on patients with chronic heart failure from March 2024 to December 2025. An analysis of the literature devoted to the diagnosis of chronic heart failure was conducted, and the search was carried out using the Google Scholar, Scopus, PubMed, and Web of Science databases. All clinical cases presented in the article were performed by the authors of the article. Results . Along with traditional methods of cardio-visualization (EchoCG, scintigraphy of myocardium), MRI with contrast agent is included in diagnostic algorithm of examination of patients with chronic heart failure, especially in complex situations. The article presents standard protocols of MRI for analysis of structural and functional changes of myocardium, contraindications to performance of MRI. On clinical observations possibilities of MRI are demonstrated in clarification of etiology of chronic heart failure in patients with reduced ejection fraction and preserved ejection fraction of left ventricle. Presented clinical cases of use of MRI for differential diagnosis of various causes of hypertrophy of myocardium of LV in patients with CHF, differential diagnosis of ischemic and non-ischemic lesion of myocardium. Conclusion . In the work are demonstrated the possibilities magnetic resonance tomography is highly informative method of diagnosis in patients with chronic heart failure, both in patients with reduced ejection fraction and in absence of its reduction.


  • Open Access

    Viral pericarditis today: Challenges in diagnosis and therapy illustrated by a “typical” clinical case

    by Zulfiya N. Sukmarova, Rimma G. Gulyan, Anna V. Torgashina, Tatiana S. Sukhinina, Evgeniia S. Aronova, Olga A. Fomicheva, Olga V. Stukalova, Dmitry V. Pevzner, Anna S. Starkova

    According to modern concepts, pericarditis is a more complex condition than was previously thought. A clinical case is presented in which, as often happens, the symptoms of pericarditis were mistaken for radicular syndrome and an acute respiratory viral infection; therefore, adequate treatment was not initially administered. It led to hyperactivation of autoinflammation, which colchicine and nonsteroidal anti-inflammatory drugs failed to control, and required high doses of glucocorticosteroids. However, at this stage, probably due to the destruction of cardiomyocytes, the activation of the autoimmune processes has already occurred, which resulted in the relapsing disease. Further management was associated with challenges in differential diagnosis, decision-making regarding the use of reserve drugs – interleukin-1 inhibitors and immunoglobulin – and the treatment of complications. It took about 1.5 years to achieve stable remission, made possible by the coordinated work of the cardiology and rheumatology centers.


  • Open Access

    Safety of using the intravenous beta-1-adrenoblocker esmolol in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention

    by O. A. Saygina, T. S. Sukhinina, M. A. Terenicheva, O. V. Stukalova, M. G. Chashchin, D. V. Pevsner

    Aim. To study the safety of using the intravenous beta-blocker (BB) esmolol in the early stages of ST-segment elevation myocardial infarction (STEMI) before primary percutaneous coronary intervention (PCI) based on an analysis of the incidence and clinical significance of adverse events (acute heart failure, hypotension, bradycardia, disorders of atrioventricular conduction (AV conduction), etc.) compared with the control group. Material and methods. The presented study is part of the randomized controlled trial ESMO-VASCMI (ClinicalTrials.gov NCT number 06376630) on the study of the cardioprotective effect of IV BB esmolol in the early stages of STEMI. The study included 121 patients (n=60 in the control group and n=61 in the esmolol group) with STEMI in the first 48 hours after the onset of symptoms contraindications to BB, who were not prescribed metoprolol before PCI due to safety concerns. The administration of esmolol began with a loading dose of 500 mcg/kg for 1 minute, followed by an infusion for 6 hours. With the development of adverse events, esmolol therapy was discontinued prematurely or temporarily suspended. Results. No statistically significant difference was observed in the frequency of adverse events potentially provoked by β1‑blocker administration between the study groups. In the esmolol group, there was a trend toward a higher incidence of bradycardia during PCI (18.03% vs 6.63%, p=0.058); hypotension (down to 70/40 mm Hg) was observed in 2 patients (3.3%), and AHF manifestations in 2 (3.3%). In 4 patients (7%), the infusion was prematurely discontinued, and in 8 (13%) it was temporarily suspended and resumed after hemodynamic stabilization. No cases of bronchospasm were detected. All cases of bradycardia and hypotension were clinically insignificant. Bradycardia developed during reperfusion with PCI, atropine was administered to 2 patients, and esmolol infusion was subsequently resumed. In the esmolol group, there was no development of stable ventricular rhythm disturbances (ventricular fibrillation (VF) or ventricular tachycardia (VT)) on the first day of the disease, in contrast to the control group (n=4; 6.67%). The differences were significant (p=0.04). The incidence of hospital deaths was low (n=1 in the control group), with no significant difference between the study and control groups (0% vs 1.7%). Conclusion. The study results confirm the favorable safety profile of esmolol. Intravenous esmolol administration reduced the incidence of life-threatening arrhythmias without increasing the frequency of conduction disturbances, bradycardia, or AHF. In most cases, discontinuation of the infusion was sufficient to manage bradycardia in the esmolol group.

  • Open Access

    Mediastinal lymphoma with cardiac involvement mimicking acute coronary syndrome: a case report

    by George M. Shaginyan, Olga V. Stukalova, Andrei V. Sherashov, Alexandra S. Shilova, Dmitry Yu. Shchekochikhin, Anait A. Oganesyan, Zainab M. Magomedova, Ekaterina S. Pershina, Шагинян Георгий Михайлович, Щекочихин Дмитрий Юрьевич

    Lymphomas constitute a heterogeneous group of cancers characterized by uncontrolled clonal proliferation of lymphoid cells. They may arise in lymph nodes and extranodal organs and tissues. Primary mediastinal large B-cell lymphoma is a rare and aggressive subtype of B-cell lymphomas, accounting for approximately 2%–3% of all non-Hodgkin lymphomas. This article presents a clinical case of primary mediastinal lymphoma with cardiac involvement in a 66-year-old female patient. The initial signs of the disease mimicked acute coronary syndrome, including chest pain, dyspnea, and cardiac rhythm disturbances. Diagnostic evaluation revealed a rapidly progressive mediastinal tumor invading the pericardium and myocardium, confirmed using modern imaging modalities (echocardiography, cardiac magnetic resonance imaging, and computed tomography) and pathological examination. Despite intensive treatment, the patient’s condition deteriorated rapidly, resulting in a fatal outcome. This case highlights the diagnostic challenges associated with cardiac and pericardial involvement in mediastinal lymphomas and demonstrates the necessity of a multidisciplinary approach in the management of such rare and aggressive diseases.


  • Open Access

    Side effects and ineffectiveness of standard therapy for idiopathic recurrent pericarditis: status of the problem and description of clinical cases. Case report

    by A A Petrukhina, A А Safiullina, Y F Osmolovskaya, I V Zhirov, O V Stukalova, V N Shitov, S N Tereshchenko

    Idiopathic recurrent pericarditis is a rare pathology characterised by recurrent inflammation in the cardiac cavity. Treatment of recurrent pericarditis is empirical and based on the use of drugs with anti-inflammatory properties. First-line drugs are non-steroidal anti-inflammatory drugs and colchicine, second-line drugs are glucocorticosteroids. This is associated with the development of undesirable side effects, which makes it impossible to continue therapy in a number of patients. This article presents two clinical cases, describes the course of the disease and the development of complications at different stages. This article demonstrates the complexity of selecting the optimal therapy in real clinical practice.

  • Open Access

    Early intravenous beta-blockers injection in patients with acute STEMI: the results of the Russian registry REGION-IM

    by T. S. Sukhinina, M. A. Terenicheva, R. G. Gulyan, R. M. Shakhnovich, O. V. Stukalova, O. A. Saygina, I. S. Yavelov, D. V. Pevsner

    Aim. To study the features of the appointment of beta-blockers (BB) therapy in the early stages of acute myocardial infarction without ST segment elevation (nonSTEMI) in real clinical practice in the Russian Federation according to the REGION registry, to analyze the frequency and use cases of Intravenous forms (IVF).Material and methods. REGION-IM is a multicenter prospective Russian registry of acute myocardial infarction (AMI). The database records demographic, anamnestic, clinical characteristics of patients, results of laboratory and instrumental examinations. The patient’s recruitment was carried out from 01.11.2020 to 30.06.2023. Overall, 10,884 patients with AMI were included in the MI REGION, of which 3252 patients with non-STEMI and 7631 — with acute myocardial infarction with ST segment elevation (STEMI), information on the appointment or refusal of IV therapy on the first day of hospitalization is present for 7597 patients with STEMI.Results. On the first day after hospitalization, 1.2% (n=91) of patients with STEMI received IVF therapy. In all cases, metoprolol was used at an average daily dose of 4.43 mg. The majority of patients (61.5%, n=56) were transferred to oral administration of BB on the first day, another 33% of patients (n=30) — the next day, 4.4% (n=4) received only intravenous BB, one (1.1%) information is missing due to the transfer to another hospital. The most common relative and absolute contraindications to the appointment of BB — acute heart failure (AHF), including Killip II, and systolic blood pressure less than 120 mmHg. They were observed in less than 20% of all patients with STEMI and in 13% and 12% of patients who received IVF. 74% of patients received oral medications on the first day. Oral forms of BB were used to initiate therapy 61 times more often than IVF of BAB (pConclusion. The results of the REGION-IM registry demonstrate an unreasonably rare frequency of IVF use in the early stages of the disease in patients with STEMI. Intravenous administration of metoprolol at an average total dose of about 4-5 mg on the first day of hospitalization with further transition to oral administration of BAB was safe. There was no significant difference in the frequency of deaths in the hospital, cases of AHF, cardiogenic shock, severe conduction disorders in the form of grade II-III AV block between the groups of patients who received and did not receive IVF.


  • Open Access

    Barth syndrome in an adult patient: an overview of the problem and case report. A review

    by M D Muksinova, Y F Osmolovskaya, I V Leontyeva, M A Galaeva, O V Stukalova, A G Beniashvili, A A Safiullina, I V Zhirov, S N Tereshchenko

    Barth syndrome is a rare genetic disease caused by abnormal cardiolipin metabolism, characterized by high mortality within 5 years of diagnosis due to heart failure and/or infectious complications. This article describes a clinical case of an adult patient with Barth syndrome. The peculiarities of the course of the disease are described, including the transformation of the hypertrophic type of cardiomyopathy into the hypokinetic type as the patient grew older. This article demonstrates the difficulty in selecting the optimal treatment of a patient with Barth syndrome in real clinical practice, in the absence of clearly prescribed recommendations and pathogenetic therapy.